The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: A pilot study

Gynecological Endocrinology

Volumn 29, Issue 3, 2013, Pages 201-204

  Beltrame, Ana Lúcia ^a   Serafini, Paulo ^a   Motta, Eduardo L A ^b   Soares Júnior, José Maria ^b   Baracat, Edmund C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bromocriptine; Fertilization; Hyperstimulation syndrome; Kidney function; VEGF

Indexed keywords

BROMOCRIPTINE; CREATININE; FOLIC ACID; LEUPRORELIN; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; SODIUM; VASCULOTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; ENDOMETRIOSIS; FEMALE; FERTILIZATION IN VITRO; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INFERTILITY; KIDNEY FUNCTION; MALE INFERTILITY; OOCYTE RETRIEVAL; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PELVIS RADIOGRAPHY; PHYSICAL EXAMINATION; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SODIUM URINE LEVEL; TRANSVAGINAL ECHOGRAPHY; TREATMENT DURATION; URINALYSIS; URINE VOLUME; UTERINE TUBE OCCLUSION;

ADULT; BRAZIL; BROMOCRIPTINE; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; FEMALE; FERTILIZATION IN VITRO; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; INFERTILITY, FEMALE; KIDNEY; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PATIENT DROPOUTS; PILOT PROJECTS; RISK; SEVERITY OF ILLNESS INDEX; SODIUM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84874330258     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.736554     Document Type: Article

References (21)

1. The Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril 2008;90:S188-S193.
2. Alvarez C, Martí-Bonmatí L, Novella-Maestre E, Sanz R, Gómez R, Fernández-Sánchez M, Simón C, Pellicer A. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007;92:2931-2937. (Pubitemid 47236352)
3. Carizza C, Abdelmassih V, Abdelmassih S, Ravizzini P, Salgueiro L, Salgueiro PT, Jine LT, et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: A prospective randomized study. Reprod Biomed Online 2008;17:751-755.
4. Grossman LC, Michalakis KG, Browne H, Payson MD, Segars JH. The pathophysiology of ovarian hyperstimulation syndrome: An unrecognized compartment syndrome. Fertil Steril 2010;94:1392-1398.
5. Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, Novella-Maestre E, Alonso-Muriel I, Sanchez-Criado J, Remohi J, et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006;147:5400-5411. (Pubitemid 44790595)
6. Oehninger S. Ovulation induction in IVF. Minerva Ginecol 2011;63:137-156.
7. Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril 2010;94:389-400.
8. Tarlatzis BC, Kolibianakis EM. GnRH agonists vs antagonists. Best Pract Res Clin Obstet Gynaecol 2007;21:57-65.
9. Melo M, Busso CE, Bellver J, Alama P, Garrido N, Meseguer M, Pellicer A, Remohí J. GnRH agonist versus recombinant HCG in an oocyte donation programme: A randomized, prospective, controlled, assessorblind study. Reprod Biomed Online 2009;19:486-492.
10. Herrero L, Pareja S, Losada C, Cobo AC, Pellicer A, Garcia-Velasco JA. Avoiding the use of human chorionic gonadotropin combined with oocyte vitrification and GnRH agonist triggering versus coasting: A new strategy to avoid ovarian hyperstimulation syndrome. Fertil Steril 2011;95:1137-1140.
11. Enskog A, Nilsson L, Brännström M. Plasma levels of free vascular endothelial growth factor(165) (VEGF(165)) are not elevated during gonadotropin stimulation in in vitro fertilization (IVF) patients developing ovarian hyperstimulation syndrome (OHSS): Results of a prospective cohort study with matched controls. Eur J Obstet Gynecol Reprod Biol 2001;96:196-201. (Pubitemid 32522560)
12. Gómez R, Simón C, Remohí J, Pellicer A. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability. Biol Reprod 2003;68:2164-2171. (Pubitemid 36687009)
13. Guo D, Jia Q, Song HY, Warren RS, Donner DB. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 1995;270:6729-6733.
14. McClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning RV Jr, Connolly DT, Robertson DM. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994;344:235-236. (Pubitemid 24229013)
15. Levin ER, Rosen GF, Cassidenti DL, Yee B, Meldrum D, Wisot A, Pedram A. Role of vascular endothelial cell growth factor in Ovarian Hyperstimulation Syndrome. J Clin Invest 1998;102:1978-1985. (Pubitemid 29001844)
16. Wang TH, Horng SG, Chang CL, Wu HM, Tsai YJ, Wang HS, Soong YK. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab 2002;87:3300-3308.
17. Chen CD, Chen HF, Lu HF, Chen SU, Ho HN, Yang YS. Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. Hum Reprod 2000;15:1037-1042.
18. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, Manseau EJ, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001;7:569-574. (Pubitemid 32448324)
19. Manno M. Can we eliminate severe ovarian hyperstimulation syndrome? Comment I. Hum Reprod 2005;20:2368-9; author reply 2369.
20. Essaïs O, Bouguerra R, Hamzaoui J, Marrakchi Z, Hadjri S, Chamakhi S, Zidi B, Ben Slama C. Efficacy and safety of bromocriptine in the treatment of macroprolactinomas. Ann Endocrinol (Paris) ;63:524-531.
21. Crosignani PG. Current treatment issues in female hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol 2006;125:152-164.